Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo.

Article Details

Citation
Copy to clipboard

Lu J, Chong CR, Hu X, Liu JO

Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo.

J Med Chem. 2006 Sep 21;49(19):5645-8.

PubMed ID
16970390 [ View in PubMed
]
Abstract

The fumagillin family of natural products inhibits angiogenesis through the irreversible inhibition of the type 2 methionine aminopeptidase (MetAP2). Herein is reported a novel fumagillin analogue named fumarranol. It is shown that, like fumagillin, fumarranol selectively inhibits MetAP2 and endothelial cell proliferation. It is also active in a mouse model of angiogenesis in vivo. Unlike TNP-470, fumarranol does not covalently bind to MetAP2. Fumarranol may serve as a lead for a new class of angiogenesis inhibitors.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
TNP-470Methionine aminopeptidase 2IC 50 (nM)1N/AN/ADetails